Suppr超能文献

甲状旁腺功能减退症:临床特征、骨骼微观结构及甲状旁腺激素替代治疗

Hypoparathyroidism: clinical features, skeletal microstructure and parathyroid hormone replacement.

作者信息

Rubin Mishaela R, Bilezikian John P

机构信息

Departamento de Medicina, Columbia University, Nova York, Estados Unidos.

出版信息

Arq Bras Endocrinol Metabol. 2010 Mar;54(2):220-6. doi: 10.1590/s0004-27302010000200019.

Abstract

OBJECTIVE

Hypoparathyroidism is a disorder in which parathyroid hormone is deficient in the circulation due most often to immunological destruction of the parathyroids or to their surgical removal. The objective of this work was to define the abnormalities in skeletal microstructure as well as to establish the potential efficacy of PTH(1-84) replacement in this disorder.

SUBJECTS AND METHODS

Standard histomorphometric and microCT analyses were performed on iliac crest bone biopsies obtained from patients with hypoparathyroidism. Participants were treated with PTH(1-84) for two years.

RESULTS

Bone density was increased and skeletal features reflected the low turnover state with greater BV/TV, Tb. Wi and Ct. Wi as well as suppressed MS and BFR/BS as compared to controls. With PTH(1-84), bone turnover and bone mineral density increased in the lumbar spine. Requirements for calcium and vitamin D fell while serum and urinary calcium concentrations did not change.

CONCLUSION

Abnormal microstructure of the skeleton in hypoparathyroidism reflects the absence of PTH. Replacement therapy with PTH has the potential to correct these abnormalities as well as to reduce the requirements for calcium and vitamin D.

摘要

目的

甲状旁腺功能减退症是一种疾病,其循环中的甲状旁腺激素通常因甲状旁腺的免疫性破坏或手术切除而缺乏。这项研究的目的是确定骨骼微观结构的异常,并确定甲状旁腺激素(1-84)替代疗法在这种疾病中的潜在疗效。

受试者和方法

对取自甲状旁腺功能减退症患者的髂嵴骨活检组织进行标准组织形态计量学和显微CT分析。参与者接受甲状旁腺激素(1-84)治疗两年。

结果

与对照组相比,骨密度增加,骨骼特征反映出低转换状态,骨体积分数(BV/TV)、骨小梁宽度(Tb.Wi)和皮质骨宽度(Ct.Wi)更高,而矿化表面(MS)和骨形成率/骨表面积(BFR/BS)受到抑制。使用甲状旁腺激素(1-84)后,腰椎的骨转换和骨矿物质密度增加。钙和维生素D的需求量下降,而血清和尿钙浓度没有变化。

结论

甲状旁腺功能减退症患者骨骼的微观结构异常反映了甲状旁腺激素的缺乏。甲状旁腺激素替代疗法有可能纠正这些异常,并减少钙和维生素D的需求量。

相似文献

1
Hypoparathyroidism: clinical features, skeletal microstructure and parathyroid hormone replacement.
Arq Bras Endocrinol Metabol. 2010 Mar;54(2):220-6. doi: 10.1590/s0004-27302010000200019.
2
Therapy of hypoparathyroidism with intact parathyroid hormone.
Osteoporos Int. 2010 Nov;21(11):1927-34. doi: 10.1007/s00198-009-1149-x. Epub 2010 Jan 22.
3
Parathyroid hormone therapy for hypoparathyroidism.
Best Pract Res Clin Endocrinol Metab. 2015 Jan;29(1):47-55. doi: 10.1016/j.beem.2014.09.001. Epub 2014 Sep 10.
5
Mini-review: new therapeutic options in hypoparathyroidism.
Endocrine. 2012 Jun;41(3):410-4. doi: 10.1007/s12020-012-9618-y. Epub 2012 Feb 7.
6
Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety.
J Clin Endocrinol Metab. 2013 Jan;98(1):137-44. doi: 10.1210/jc.2012-2984. Epub 2012 Nov 15.
7
Management of Hypoparathyroidism: Present and Future.
J Clin Endocrinol Metab. 2016 Jun;101(6):2313-24. doi: 10.1210/jc.2015-3910. Epub 2016 Mar 3.
8
Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety.
J Clin Endocrinol Metab. 2016 Jul;101(7):2742-50. doi: 10.1210/jc.2015-4135. Epub 2016 May 4.
9
Skeletal Manifestations of Hypoparathyroidism.
Endocrinol Metab Clin North Am. 2018 Dec;47(4):825-837. doi: 10.1016/j.ecl.2018.07.008.
10
Use of parathyroid hormone in hypoparathyroidism.
J Endocrinol Invest. 2013 Dec;36(11):1121-7. doi: 10.1007/BF03346763.

引用本文的文献

1
Open-label extension of a randomized trial investigating safety and efficacy of rhPTH(1-84) in hypoparathyroidism.
JBMR Plus. 2024 Jan 5;8(3):ziad010. doi: 10.1093/jbmrpl/ziad010. eCollection 2024 Mar.
2
Hypoparathyroidism: Musculoskeletal Manifestations Related to Parathormone Deficiency.
Curr Rheumatol Rev. 2024;20(5):488-500. doi: 10.2174/0115733971267895231227102539.
3
Interoceptive regulation of skeletal tissue homeostasis and repair.
Bone Res. 2023 Sep 5;11(1):48. doi: 10.1038/s41413-023-00285-6.
4
Safety and Efficacy of PTH 1-34 and 1-84 Therapy in Chronic Hypoparathyroidism: A Meta-Analysis of Prospective Trials.
J Bone Miner Res. 2022 Jul;37(7):1233-1250. doi: 10.1002/jbmr.4566. Epub 2022 May 20.
5
Risk of Hypocalcemia and the Need to Augment Calcium Supplementation After Total Thyroidectomy.
Indian J Surg Oncol. 2022 Mar;13(1):7-10. doi: 10.1007/s13193-020-01098-3. Epub 2020 May 24.
6
A Rapid Intraoperative Parathyroid Hormone Assay Based on the Immune Colloidal Gold Technique for Parathyroid Identification in Thyroid Surgery.
Front Endocrinol (Lausanne). 2021 Apr 22;11:594745. doi: 10.3389/fendo.2020.594745. eCollection 2020.
7

本文引用的文献

1
Therapy of hypoparathyroidism with intact parathyroid hormone.
Osteoporos Int. 2010 Nov;21(11):1927-34. doi: 10.1007/s00198-009-1149-x. Epub 2010 Jan 22.
2
Three dimensional cancellous bone structure in hypoparathyroidism.
Bone. 2010 Jan;46(1):190-5. doi: 10.1016/j.bone.2009.09.020. Epub 2009 Sep 25.
3
Anti-parathyroid and anti-calcium sensing receptor antibodies in autoimmune hypoparathyroidism.
Endocrinol Metab Clin North Am. 2009 Jun;38(2):437-45, x. doi: 10.1016/j.ecl.2009.01.001.
4
Dynamic and structural properties of the skeleton in hypoparathyroidism.
J Bone Miner Res. 2008 Dec;23(12):2018-24. doi: 10.1359/jbmr.080803.
5
Clinical practice. Hypoparathyroidism.
N Engl J Med. 2008 Jul 24;359(4):391-403. doi: 10.1056/NEJMcp0803050.
6
DiGeorge syndrome/velocardiofacial syndrome: the chromosome 22q11.2 deletion syndrome.
Adv Exp Med Biol. 2007;601:37-49. doi: 10.1007/978-0-387-72005-0_4.
7
Hypocalcemic hypercalciuria during vitamin D and dihydrotachysterol therapy of hypoparathyroidism.
J Clin Endocrinol Metab. 1958 Mar;18(3):246-52. doi: 10.1210/jcem-18-3-246.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验